Patent ID: 11957760
Assignee: ELUCIDA ONCOLOGY, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A nanoparticle-drug conjugate (NDC) comprising:
(a) a silica nanoparticle;
(b) polyethylene glycol (PEG) that is covalently bonded to the surface of the silica nanoparticle;
(c) a targeting ligand comprising folic acid, wherein the targeting ligand is attached to the silica nanoparticle through a first spacer group; and
(d) a linker-payload conjugate, wherein:
(i) the payload is exatecan;
(ii) the linker-payload conjugate is attached to the silica nanoparticle through a second spacer group;
(iii) the linker is a protease-cleavable linker; and
(iv) the exatecan is released upon cleavage of the linker,, wherein the first spacer group and the second spacer group each comprise a structure of Formula (NP):, , wherein
x is an integer of 0 to 20;
the silicon atom (Si) is a part of the silica nanoparticle; and
the  adjacent to the triazole moiety denotes a point of attachment to the targeting ligand or the linker-payload conjugate, either directly or indirectly.